July 19, 2017
An AbbVie Inc. executive who monitored the safety of the company's products told an Illinois federal jury Wednesday that the U.S. Food and Drug Administration had all the company's information on heart attacks suffered by people on AndroGel but repeatedly declined to ask for a study on the risk.
July 17, 2017
A man suing AbbVie Inc. over its testosterone replacement therapy, AndroGel, told an Illinois federal jury Monday that the benefits he received from using the gel did not outweigh its risk of heart attack.
July 14, 2017
An expert on pharmaceutical regulation testifying in a trial against AbbVie Inc. over testosterone therapy drug AndroGel told an Illinois federal jury Friday that there was enough evidence of a connection between the drug and heart attacks to warrant further testing and an updated label.
July 13, 2017
There is enough evidence to connect testosterone therapy drugs to an increased risk of heart attack, a cardiologist testifying in a trial against AbbVie Inc. over its AndroGel product told an Illinois federal jury Thursday.
July 10, 2017
The former commissioner of the U.S. Food and Drug Administration told an Illinois federal jury Monday that the ads AbbVie Inc. put out for its product AndroGel misleadingly promoted it for uses beyond what the regulator approved.
July 06, 2017
AbbVie Inc. told an Illinois federal jury Thursday that there are no studies definitively showing a connection between heart attacks and its testosterone product AndroGel, detailing its defense in a lawsuit accusing the drugmaker of downplaying the drug's risks.
July 05, 2017
AbbVie Inc. knew its product AndroGel wasn't approved to treat age-related drops in testosterone, but the company marketed it for that while downplaying an associated risk of heart attacks, attorneys for a man who nearly died after using it told an Illinois federal jury on Wednesday.